SMTI Sanara MedTech Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 714256 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.8%
TTM net income YoY92.0%
TTM EPS YoY91.9%
Revenue 3-yr CAGR21.4%
Net income 3-yr CAGR—
Margins
Gross margin93.0%
Operating margin5.6%
Net margin-2.7%
FCF margin6.5%
EBITDA margin7.8%
Returns
ROE-43.7%
ROA-4.2%
ROIC (approx.)13.3%
Asset turnover1.56x
Leverage & solvency
Liabilities / assets89.4%
Debt / equity6.10x
Current ratio2.24x
Interest coverage0.86x
Cash quality & payout
Operating cash flow / net income-2.46x
Accruals ratio-14.6%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $28.43M | $28.14M | $27.80M | $27.55M | $26.33M | $25.80M | $23.43M | $26.31M |
| Cost of revenue | $2.10M | $1.98M | $1.92M | $1.87M | $1.87M | $1.94M | $1.83M | $2.25M |
| Gross profit | $26.33M | $26.16M | $25.87M | $25.67M | $24.46M | $23.87M | $21.60M | $24.06M |
| R&D expense | $723,717 | $1.15M | $759,592 | $2.04M | $1.03M | $1.06M | $950,359 | $883,400 |
| SG&A expense | $24.25M | $22.60M | $21.88M | $20.08M | $19.88M | $19.63M | $19.13M | $20.22M |
| Operating income | $736,005 | $1.78M | $2.65M | $1.05M | $2.94M | $2.49M | $825,530 | $2.26M |
| Interest expense | $1.81M | $1.81M | $1.80M | $1.83M | $1.82M | $1.79M | $1.32M | $1.29M |
| Net income | -$1.41M | -$452,864 | $458,957 | -$1.61M | -$30.41M | -$2.01M | -$3.53M | -$1.54M |
| EBITDA | $1.35M | $2.40M | $3.23M | $1.72M | $3.55M | $3.18M | $1.95M | $3.87M |
| EPS (basic) | — | -0.05 | 0.05 | — | -3.52 | -0.23 | -0.41 | — |
| EPS (diluted) | — | -0.05 | 0.05 | — | -3.40 | -0.23 | -0.41 | — |
| Weighted avg. shares (diluted) | 8.78M | 8.66M | 8.99M | — | 8.94M | 8.93M | 8.57M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $16.79M | $15.42M | $13.59M | $16.58M | $14.94M | $16.96M | $20.69M | $15.88M |
| Receivables | $13.89M | $12.57M | $13.62M | $12.00M | — | — | — | — |
| Inventory | $3.30M | $3.46M | $3.12M | $3.95M | $3.39M | $3.51M | $3.16M | $2.75M |
| Current assets | $36.40M | $32.20M | $31.20M | $33.54M | $31.23M | $33.67M | $36.84M | $33.31M |
| PP&E, net | $316,869 | $426,934 | $458,880 | $456,962 | $417,208 | $8.90M | $2.06M | $432,317 |
| Goodwill | $3.60M | $3.60M | $3.60M | $3.60M | $3.60M | $3.60M | $3.60M | $3.60M |
| Intangibles | $16.70M | $17.28M | $17.86M | $18.64M | $21.10M | $40.99M | $42.01M | $23.48M |
| Total assets | $72.24M | $69.15M | $69.28M | $72.94M | $71.09M | $98.77M | $96.38M | $88.09M |
| Current liabilities | $16.28M | $12.49M | $13.70M | $18.63M | $17.36M | $14.88M | $13.28M | $15.29M |
| Long-term debt | $46.72M | $46.48M | $46.23M | $45.97M | $45.09M | $44.22M | $43.40M | $30.69M |
| Total debt | $46.72M | $46.48M | $46.23M | $45.97M | $45.09M | $44.22M | $43.40M | $30.69M |
| Total liabilities | $64.57M | $61.21M | $62.26M | $67.01M | $64.95M | $63.38M | $59.71M | $49.18M |
| Shareholders' equity | $7.67M | $7.94M | $7.03M | $5.94M | $6.15M | $35.40M | $36.67M | $39.40M |
| Net debt | $29.94M | $31.06M | $32.63M | $29.39M | $30.15M | $27.26M | $22.71M | $14.81M |
| Shares outstanding | 9.18M | 9.19M | 9.17M | 8.95M | 8.93M | 8.90M | 8.90M | 8.75M |
| Cash flow statement | ||||||||
| Operating cash flow | $3.90M | $2.04M | -$2.47M | $3.95M | $2.18M | $2.66M | -$2.00M | $932,047 |
| Capital expenditure | $0 | $5,280 | $43,772 | $82,159 | $1.06M | $1.76M | $1.72M | $72,172 |
| Free cash flow | $3.90M | $2.03M | -$2.51M | $3.86M | $1.12M | $902,652 | -$3.72M | $859,875 |
| Investing cash flow | -$1.76M | -$5,280 | -$43,772 | -$2.45M | -$3.42M | -$3.93M | -$5.18M | -$129,994 |
| Financing cash flow | -$779,537 | -$206,481 | -$475,219 | $139,427 | -$774,749 | -$2.47M | $11.99M | -$1.20M |
| Depreciation & amortization | $613,044 | $619,111 | $587,252 | $668,396 | $610,899 | $688,546 | $1.12M | $1.61M |
| Stock-based compensation | $1.27M | $1.50M | $1.03M | $1.18M | $41,948 | $130,174 | $1.30M | $1.20M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.